Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

HUMA 11.22.2024

SERA-AI Powered Highlights
Drug:HUMA-ATEV ATEV
Diseases:End Stage Renal Disease
Date of Upcoming Event:2024-11-23
Name of Upcoming Event:51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons
Full Press ReleaseSEC FilingsOur HUMA Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
  • 01.13.2025 - Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
  • 12.20.2024 - Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Recent Filings

  • 12.20.2024 - EX-99.1 EX-99.1
  • 12.20.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.20.2024 - 8-K Current report
PDF Version

DURHAM, N.C.,Nov. 22, 2024(GLOBE NEWSWIRE) --Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety ofHumacyte'sacellular tissue engineered vessel (ATEVTM) with autologous AV fistulas in patients with end stage renal disease at the 51stAnnual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) inNew York, NYonNovember 23, 2024.

Details of the presentation are as follows:

Presentation Title:Results of a Phase 3 Study Comparing Efficacy and Safety of Humacyte Tissue-Engineered Vessel with Autologous AV Fistulas in Patients with End Stage Renal Disease

Presenter:Dr.Charles Keith Ozaki, MD, Vascular Surgeon and Director ofVascular Surgery Researchat Brigham and Women’s Hospital;John A. Mannick Professorof Surgery atHarvard Medical School

Session Title:Novel Technologies in Hemodialysis Access

Session Date/Time:Saturday, November 23, 2024, 2:15 –2:22 PM ET

For more information on the 51stAnnual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH), pleaseclick here.

The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. The ATEV is an investigational product and has not been approved for sale by the Food and Drug Administration or any international regulatory agency.

Humacyte Investor Contact:Joyce AllaireLifeSci Advisors LLC+1-617-435-6602jallaire@lifesciadvisors.cominvestors@humacyte.com

Humacyte Media Contact:Rich LuchettePrecision Strategies+1-202-845-3924rich@precisionstrategies.commedia@humacyte.com

Primary Logo

Source: Humacyte, Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com